Specific features of the bioequivalence study of drugs - analogs of endogenous compounds
This paper presents an analysis of leading foreign regulatory authorities’ requirements for the bioequivalence studies of medicinal products containing analogues of endogenous substances. US Food and Drug Administration, European Medicines Agency, and Eurasian Economic Union’s approaches are discuss...
Main Authors: | V. K. Adonin, D. P. Romodanovskiy, R. R. Niyazov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
NEICON ISP LLC
2018-02-01
|
Series: | Ведомости Научного центра экспертизы средств медицинского применения |
Subjects: | |
Online Access: | https://www.vedomostincesmp.ru/jour/article/view/44 |
Similar Items
-
CLINICAL DEVELOPMENT STRATEGY FOR COPIES OF PREVIOUSLY REGISTERED DRUGS. PART 3. PROTOCOL OF CLINICAL TRIAL OF BIOEQUIVALENCE
by: K. A. Yatsenko, et al.
Published: (2019-01-01) -
Evaluation of endogenous compounds pharmacokinetics as illustrated by calcium
by: N. N. Eremenko, et al.
Published: (2018-02-01) -
Risks of clinical trial protocol amendments according to duration of the trial
by: A. A. Eleskina, et al.
Published: (2023-07-01) -
Highly variable medicines - specific aspects of bioequivalence studies
by: D. P. Romodanovsky, et al.
Published: (2018-02-01) -
MOTIVATION AND PARTICIPATION EXPERIENCE OF HEALTHY VOLUNTEERS IN THE CLINICAL TRIALS OF BIOEQUIVALENCE IN RUSSIA
by: I. V. Mareev, et al.
Published: (2019-01-01)